People of Chinese (originating from China, Taiwan or Hong Kong) and South Asian (originating from India, Pakistan, Bangladesh or Sri Lanka) descent are among the fastest-growing ethnic populations in North America. The burden of stroke and subsequent disability and death in these groups is likewise growing exponentially. Secondary prevention therapy after acute stroke is a core component of stroke care, essential to reducing the risk of recurrent stroke and death. As such, health care organizations aim to create equitable access to stroke care across all populations regardless of ethnicity.

However, it remains unknown whether there are differences in secondary prevention care after stroke in South Asian and Chinese populations. Studies indicate that South Asian and Chinese patients are less likely to meet targets for vascular risk reduction than their white counterparts. These groups may also hold a different understanding on vascular disease or may have communication barriers that affect use of secondary prevention therapies. The aim of this population-based study was to evaluate potential ethnic differences in secondary prevention pharmacotherapy after acute stroke. Specifically, we compared prescription filling for the guideline-recommended treatments within 1 year after hospital discharge for acute ischemic stroke and the combination of angiotensin-converting-enzyme (ACE) inhibitor and diuretic, and the combination of ACE inhibitor, diuretic and statin within 1 year after ischemic or primary intracerebral hemorrhagic stroke.

## Results

There were 118,362 patients with acute stroke (3430 Chinese, 2075 South Asian and 112,857 other Canadians). Among those with ischemic stroke (n = 108,699), Chinese patients were less likely than other Canadian patients to fill prescriptions for the combination of ACE inhibitor, diuretic and statin (adjusted odds ratio [OR] 0.64 [95% confidence interval (CI) 0.55–0.74]) and, in those with atrial fibrillation, for warfarin (adjusted OR 0.75 [95% CI 0.59–0.95]). There were no differences in filling of prescriptions for antihypertensive therapy overall between the 3 groups. Among patients with intracerebral hemorrhagic stroke (n = 9683), Chinese patients were less likely than other Canadian patients to fill prescriptions for the combination of ACE inhibitor and diuretic (adjusted OR 0.51 [95% CI 0.38–0.69]), and South Asians were more likely than other Canadian patients to fill prescriptions for any antihypertensive agent (adjusted OR 1.73 [95% CI 1.21–2.49]).

## Interpretation

We identified ethnic differences in filling of prescriptions for several secondary prevention medications after acute stroke. The reasons underlying these differences need to be investigated.
Methods

Setting
This was a retrospective population-based analysis using administrative data from Ontario (1997–2011) and British Columbia (1997–2009). We selected these 2 provinces as they include the largest nonwhite populations in Canada. The differing time periods reflect the maximally allowable data collection periods for the 2 provinces at the time of data request. To our knowledge, there were no major drug policy changes during 2010–2011 in Ontario.

Data sources
We used the Discharge Abstract Database, which includes all inpatient records with International Classification of Diseases, 9th revision (ICD-9) and 10th revision (ICD-10) diagnostic codes. The Ontario Drug Benefit and British Columbia’s PharmaNet databases contain the Drug Identification Number used to identify all drug claims filled at nonhospital pharmacies. Novel orally administered anticoagulants were approved for atrial fibrillation only in October 2010 and so were not included in this analysis. Data on over-the-counter medications including acetylsalicylic acid were also not available. We obtained deidentified linked health data sets through the Institute for Clinical Evaluative Sciences in Ontario and Population Data BC with approval of relevant data stewards.

Stroke population
All residents aged 66 years or more discharged alive from hospital after acute ischemic or hemorrhagic stroke were included. Prescription data in Ontario are available only for those aged 65 years or more, and we looked back 6 months to determine medication prescriptions filled before the stroke. We identified stroke cases using validated, most responsible diagnosis coding with a positive predictive value of 85% or greater for ischemic stroke (ICD-9 434, 436, or ICD-10-CA I63, I64) and primary intracerebral hemorrhage (ICD-9 431 and ICD-10 I61.x). The Ontario Drug Benefit and British Columbia’s PharmaNet databases contain the Drug Identification Number used to identify all drug claims filled at nonhospital pharmacies. Novel orally administered anticoagulants were approved for atrial fibrillation only in October 2010 and so were not included in this analysis. Data on over-the-counter medications including acetylsalicylic acid were also not available. We obtained deidentified linked health data sets through the Institute for Clinical Evaluative Sciences in Ontario and Population Data BC with approval of relevant data stewards.

Pharmacotherapy for secondary prevention
Among patients with ischemic stroke, as the 2 primary aims, we determined the proportion who filled at least 1 prescription for the optimal medication bundle (diuretic, ACE inhibitor and statin or, if they had atrial fibrillation, warfarin). The American Heart Association and Hypertension Canada guidelines for secondary prevention therapy of stroke recommend the combination of ACE inhibitor and diuretic as the preferred antihypertensive therapy for both ischemic and hemorrhagic stroke, statins for atherosclerotic ischemic stroke and warfarin in patients with ischemic stroke and atrial fibrillation. As secondary aims, we investigated the combination of any antihypertensive and statin, and individual medications including ACE inhibitors, angiotensin-receptor blockers, diuretics, calcium-channel blockers and β-blockers. For patients with primary intracerebral hemorrhage, the primary aim was to evaluate prescription filling for the combination of ACE inhibitor and diuretic, and, for the secondary aim, any antihypertensive agent. We determined prescription filling in patients discharged alive and within 1 year of discharge from hospital. Drug costs may influence the decision to fill a prescription. In Ontario and British Columbia, costs for medications are subsidized for low-income older people. In Ontario, those aged 65 years or more pay a $100 deductible each year for medications and $6.11, on average, for each approved prescription filled, depending on their income. Those with a low income can have their deductible waived and pay up to $2 for each prescription. In British Columbia, an income-based deductible program was initiated in 2003 whereby patients pay a deductible based on income and pay 25% of medication costs thereafter.

Categorizing ethnicity
To determine Chinese and South Asian ethnicity, we used Quan and colleagues’s surname list for Chinese names and the Nam Pehchan surname algorithm for South Asian names. Intermarriage does not affect the categorization substantially. The remaining patients were categorized as “other Canadians,” this group encompassed white patients (93%) and non-Chinese, non-South Asian visible minority groups.

Other baseline characteristics
We obtained history of prior congestive heart failure, atrial fibrillation, hypertension, diabetes and myocardial infarction from the Discharge Abstract Database using validated ICD coding algorithms at the time of admission for acute stroke. We assigned socioeconomic status using median neighbourhood income based on each patient’s postal code.

Statistical analysis
We compared categorical variables using the χ² test and continuous variables using one-way analysis of variance, where appropriate. We constructed hierarchical risk-adjusted logistic regression models for either stroke type to determine the association of ethnicity with prescription filling, adjusting for neighbourhood income quintile, age, sex, most responsible physician (family doctor v. specialist), prior medication use, and history of atrial fibrillation, hypertension, diabetes, dyslipidemia, myocardial infarction or congestive heart failure. We used multilevel modelling to account for potential clustering at the level of province and hospital.

Ethics approval
The study was approved by the research ethics boards of the University of Toronto and the University of British Columbia.

Results
There were 108 699 patients with acute ischemic stroke and 9663 patients with primary intracerebral hemorrhagic stroke aged 66 years or more. Ischemic stroke was more common than hemorrhagic stroke for all ethnic groups (Chinese 84.1%, South Asian 90.4%, other Canadians 92.1%). Of the 108 699 patients with ischemic stroke, 2884 were Chinese, 1875 were South Asian, and 103 940 were other Canadians. The corresponding values for primary intracerebral hemorrhagic stroke were 546, 200 and 8917.
Baseline characteristics
In the ischemic stroke subgroup, both Chinese and South Asian patients were more likely than other Canadian patients to occupy lower socioeconomic status quintiles, to have hypertension, to have diabetes and to be admitted by an Internal Medicine or Neurology (Table 1). Chinese patients were less likely than South Asian or other Canadian patients to fill a prescription for an ACE inhibitor but more likely to fill a prescription for an angiotensin-receptor blocker. However, the proportion of patients filling prescriptions for antihypertensive medications was similar among 3 groups. Among patients with atrial fibrillation, other Canadian patients were more

| Characteristic                        | Chinese (n = 2884) | Other Canadians (n = 103,940) | South Asian (n = 1875) | p value |
|---------------------------------------|--------------------|--------------------------------|------------------------|---------|
| Age, yr                               |                    |                                |                        |         |
| 65–74                                 | 967 (33.5)         | 30,490 (29.3)                 | 815 (43.5)             | < 0.001 |
| 75–84                                 | 1328 (46.0)        | 48,468 (46.6)                 | 775 (41.3)             |         |
| ≥ 85                                  | 589 (20.4)         | 24,982 (24.0)                 | 285 (15.2)             |         |
| Women                                 | 1592 (55.2)        | 56,072 (53.9)                 | 943 (50.3)             | 0.003   |
| Live in British Columbia             | 1050 (36.4)        | 18,677 (18.0)                 | 716 (38.2)             | < 0.001 |
| Median neighbourhood income quintile*|                    |                                |                        |         |
| Q1 (lowest)                          | 793 (27.5)         | 23,755 (22.8)                 | 530 (28.3)             | < 0.001 |
| Q2                                    | 677 (23.5)         | 22,435 (21.6)                 | 460 (24.5)             |         |
| Q3                                    | 515 (17.8)         | 20,084 (19.3)                 | 406 (21.6)             |         |
| Q4                                    | 489 (17.0)         | 18,390 (17.7)                 | 261 (13.9)             |         |
| Q5 (highest)                         | 386 (13.4)         | 18,419 (17.7)                 | 208 (11.1)             |         |
| Hypertension                          | 675 (23.4)         | 20,598 (19.8)                 | 477 (25.4)             | < 0.001 |
| Diabetes                              | 337 (11.7)         | 8,661 (8.3)                   | 301 (16.0)             | < 0.001 |
| Acute myocardial infarction           | 76 (2.6)           | 4,768 (4.6)                   | 75 (4.0)               | < 0.001 |
| Heart failure                         | 100 (3.5)          | 5,073 (4.9)                   | 101 (5.4)              | 0.001   |
| Atrial fibrillation                   | 363 (12.6)         | 12,368 (11.9)                 | 151 (8.0)              | < 0.001 |
| Admitting physician                   |                    |                                |                        |         |
| Family physician                      | 851 (29.5)         | 55,441 (53.3)                 | 761 (40.6)             | < 0.001 |
| Internist                             | 1,291 (44.8)       | 24,795 (23.8)                 | 627 (33.4)             |         |
| Neurologist                           | 455 (15.8)         | 14,074 (13.5)                 | 322 (17.2)             |         |
| Other                                 | 287 (10.0)         | 9,630 (9.3)                   | 165 (8.8)              |         |
| Medication(s) prescribed in 6 mo before stroke | | | | |
| ACE inhibitor                         | 762 (26.4)         | 37,309 (35.9)                 | 687 (36.6)             | < 0.001 |
| β-blocker                             | 840 (29.1)         | 31,066 (29.9)                 | 548 (29.2)             | 0.6     |
| Angiotensin-receptor blocker          | 451 (15.6)         | 8,662 (8.3)                   | 215 (11.5)             | < 0.001 |
| Calcium-channel blocker               | 864 (30.0)         | 28,407 (27.3)                 | 558 (29.8)             | 0.006   |
| Diuretic                              | 593 (20.6)         | 32,328 (31.1)                 | 504 (26.9)             | < 0.001 |
| Any antihypertensive                  | 1,970 (68.3)       | 72,111 (69.4)                 | 1,301 (69.4)           | 0.5     |
| Acetylsalicylic acid                  | 411 (14.2)         | 14,561 (14.0)                 | 310 (16.5)             | 0.007   |
| Statin                                | 631 (21.9)         | 24,720 (23.8)                 | 557 (29.7)             | < 0.001 |
| Warfarin†                             | 71 (19.6)          | 3,410 (27.6)                  | 37 (24.5)              | 0.002   |

Note: ACE = angioten-converting-enzyme.  
*Missing for 0.8% of patients.  
†Among patients with atrial fibrillation.
likely to have filled a prescription for warfarin before stroke than Chinese or South Asian patients.

Among patients with primary intracerebral hemorrhagic stroke, South Asian and Chinese patients were more likely than other Canadians to occupy lower socioeconomic status quintiles and to have diabetes (Table 2). Compared to South Asian and other Canadian patients, Chinese patients were more likely to be cared for by specialists rather than family

Table 2: Baseline characteristics among older patients with primary intracerebral hemorrhagic stroke by ethnicity

| Characteristic                          | Ethnicity; no. (%) of patients |   |   |   |
|----------------------------------------|-------------------------------|---|---|---|
|                                        | Chinese                       | Other Canadians | South Asian |   |
|                                        | n = 546                       | n = 8917        | n = 200     |   |
| Age, yr                                |                               |                |             |   |
| 65–74                                  | 197 (36.1)                    | 2982 (33.4)    | 89 (44.5)   | 0.01 |
| 75–84                                  | 255 (46.7)                    | 4186 (46.9)    | 78 (39.0)   |   |
| ≥ 85                                   | 94 (17.2)                     | 1749 (19.6)    | 33 (16.5)   |   |
| Women                                  | 289 (52.9)                    | 4665 (52.3)    | 102 (51.0)  | 0.9 |
| Live in British Columbia               | 220 (40.3)                    | 1421 (15.9)    | 71 (35.5)   | < 0.001 |
| Median neighbourhood income quintile*  |                               |                |             |   |
| Q1 (lowest)                            | 152 (27.8)                    | 1829 (20.5)    | 59 (29.5)   | < 0.001 |
| Q2                                     | 120 (22.0)                    | 1890 (21.2)    | 46 (23.0)   |   |
| Q3                                     | 110 (20.1)                    | 1747 (19.6)    | 41 (20.5)   |   |
| Q4                                     | 102 (18.7)                    | 1679 (18.8)    | 27 (13.5)   |   |
| Q5 (highest)                           | 60 (11.0)                     | 1705 (19.1)    | 27 (13.5)   |   |
| Hypertension                           | 355 (65.0)                    | 6118 (68.6)    | 123 (61.5)  | 0.02 |
| Diabetes                               | 62 (11.4)                     | 830 (9.3)      | 28 (14.0)   | 0.03 |
| Acute myocardial infarction            | 21 (3.8)                      | 287 (3.2)      | 7 (3.5)     | 0.7 |
| Heart failure                           | 12 (2.2)                      | 267 (3.0)      | < 5 (< 1.0) | 0.2 |
| Atrial fibrillation                     | 30 (5.5)                      | 647 (7.2)      | < 5 (< 1.0) | 0.01 |
| Admitting physician                    |                               |                |             |   |
| Family physician                       | 149 (27.3)                    | 3617 (40.6)    | 65 (32.5)   | < 0.001 |
| Internist                              | 196 (35.9)                    | 2129 (23.9)    | 50 (25.0)   |   |
| Neurologist                            | 82 (15.0)                     | 1360 (15.2)    | 34 (17.0)   |   |
| Neurosurgeon                           | 72 (13.2)                     | 1023 (11.5)    | 26 (13.0)   |   |
| Other                                  | 47 (8.6)                      | 788 (8.8)      | 25 (12.5)   |   |
| Medication(s) prescribed in 6 mo before stroke | | |
| ACE inhibitor                          | 120 (22.0)                    | 2699 (30.3)    | 75 (37.5)   | < 0.001 |
| β-blocker                              | 111 (20.3)                    | 2120 (23.8)    | 41 (20.5)   | 0.1 |
| Angiotensin-receptor blocker           | 68 (12.4)                     | 667 (7.5)      | 9 (4.5)     | < 0.001 |
| Calcium-channel blocker                | 122 (22.3)                    | 1771 (19.9)    | 34 (17.0)   | 0.2 |
| Diuretic                               | 81 (14.8)                     | 2006 (22.5)    | 38 (19.0)   | < 0.001 |
| Any antihypertensive agent             | 318 (58.2)                    | 5181 (58.1)    | 114 (57.0)  | 1.0 |
| Statin                                 | 122 (22.3)                    | 2067 (23.2)    | 45 (22.5)   | 0.9 |
| Acetylsalicylic acid                   | 50 (9.2)                      | 891 (10.0)     | 30 (15.0)   | 0.05 |
| Warfarin†                              | 17 (56.7)                     | 358 (55.3)     | –           | 0.3 |

Note: ACE = angioten-converting-enzyme.
*Missing for 0.7% of patients.
†Among patients with atrial fibrillation.
physicians. Chinese patients were least likely to have filled prescriptions for antihypertensive therapy before the stroke, whereas South Asians were most likely to have filled such prescriptions.

**Pharmacotherapy for secondary prevention**

Unadjusted rates of filling of prescriptions for secondary prevention therapy within 1 year after discharge from hospital after acute stroke are presented in Table 3 and Table 4.

### Table 3: Proportions of patients who filled prescriptions for secondary prevention therapy within 1 year after ischemic stroke by ethnicity

| Medication                              | Ethnicity; no. (%) of patients | p value |
|-----------------------------------------|--------------------------------|---------|
|                                         | Chinese n = 2884 | Other Canadians n = 103 940 | South Asian n = 1875 |       |
| ACE inhibitor                           | 1263 (43.8) | 51 528 (49.6) | 1015 (54.1) | < 0.001 |
| Angiotensin-receptor blocker            | 574 (19.9) | 10 785 (10.4) | 269 (14.3) | < 0.001 |
| ACE inhibitor or angiotensin-receptor blocker | 1651 (57.2) | 58 611 (56.4) | 1176 (62.7) | < 0.001 |
| Diuretic                                | 746 (25.9) | 39 651 (38.1) | 580 (30.9) | < 0.001 |
| Calcium-channel blocker                 | 983 (34.1) | 32 708 (31.5) | 702 (37.4) | < 0.001 |
| β-blocker                               | 892 (30.9) | 34 439 (33.1) | 657 (35.0) | 0.009 |
| ACE inhibitor or diuretic               | 1583 (54.9) | 66 196 (63.7) | 1210 (64.5) | < 0.001 |
| ACE inhibitor + diuretic                | 426 (14.8) | 24 983 (24.0) | 385 (20.5) | < 0.001 |
| Any antihypertensive agent              | 2193 (76.0) | 80 138 (77.1) | 1494 (79.7) | 0.01 |
| Statin                                  | 1254 (43.5) | 43 550 (41.9) | 953 (50.8) | < 0.001 |
| Statin or ACE inhibitor or diuretic     | 1988 (68.9) | 75 846 (73.0) | 1415 (75.5) | < 0.001 |
| Statin + ACE inhibitor + diuretic       | 231 (8.0) | 13 119 (12.6) | 254 (13.5) | < 0.001 |
| Statin or antihypertensive              | 2295 (79.6) | 83 764 (80.6) | 1551 (82.7) | 0.03 |
| Statin + antihypertensive               | 1152 (39.9) | 39 924 (38.4) | 896 (47.8) | < 0.001 |
| Warfarin*                               | 249 (68.6) | 9014 (72.9) | 109 (72.2) | 0.2 |

Note: ACE = angiotensin-converting-enzyme. *Among patients with atrial fibrillation.

### Table 4: Proportions of patients who filled prescriptions for secondary prevention therapy within 1 year after primary intracerebral hemorrhagic stroke by ethnicity

| Medication                              | Ethnicity; no. (%) of patients | p value |
|-----------------------------------------|--------------------------------|---------|
|                                         | Chinese n = 546 | Other Canadians n = 8917 | South Asian n = 200 |       |
| ACE inhibitor                           | 200 (36.6) | 3924 (44.0) | 118 (59.0) | < 0.001 |
| Angiotensin-receptor blocker            | 80 (14.6) | 827 (9.3) | 23 (11.5) | 0.001 |
| ACE inhibitor or angiotensin-receptor blocker | 252 (46.2) | 4428 (49.6) | 127 (63.5) | 0.001 |
| Diuretic                                | 109 (20.0) | 2845 (31.9) | 57 (28.5) | < 0.001 |
| Calcium-channel blocker                 | 185 (33.9) | 2716 (30.4) | 63 (31.5) | 0.2 |
| β-blocker                               | 139 (25.4) | 2682 (30.1) | 64 (32.0) | 0.1 |
| ACE inhibitor or diuretic               | 253 (46.3) | 4942 (55.4) | 131 (65.5) | < 0.001 |
| ACE inhibitor + diuretic                | 56 (10.2) | 1827 (20.5) | 44 (22.0) | < 0.001 |
| Any antihypertensive                    | 352 (64.5) | 6125 (68.7) | 155 (77.5) | 0.003 |

Note: ACE = angiotensin-converting-enzyme.
Ischemic stroke
In the ischemic stroke subgroup, filling of prescriptions for statins was relatively low in all groups. Compared to the other groups, Chinese patients were less likely to fill prescriptions for ACE inhibitor and diuretic combination therapy ($p < 0.001$) and for the optimal bundle of ACE inhibitor, diuretic and statin ($p < 0.001$). South Asians were more likely than the 2 other groups to fill prescriptions for any antihypertensive ($p = 0.01$) and for statins ($p < 0.001$), but only 254 South Asians (13.5%) filled prescriptions for the optimal bundle of diuretic, ACE inhibitor and statin. Only 68.6%–72.9% of patients with atrial fibrillation filled prescriptions for warfarin after ischemic stroke; there was no difference between ethnic groups in the unadjusted analysis ($p = 0.2$).

In the adjusted analysis, there were no differences between groups in prescription filling for any antihypertensive among patients with ischemic stroke (Table 5). However, fewer Chinese patients than other Canadian patients filled prescriptions for the optimal therapy bundle of ACE inhibitor, diuretic and statin (adjusted odds ratio [OR] 0.64 [95% confidence interval (CI) 0.55–0.74]). Among patients with atrial fibrillation, fewer Chinese patients than other Canadian patients filled prescriptions for warfarin (adjusted OR 0.75 [95% CI 0.59–0.95]).

There was no difference in prescription filling of the optimal therapy bundle of ACE inhibitor, diuretic and statin between South Asian and other Canadian patients.

Primary intracerebral hemorrhagic stroke
For patients with primary intracerebral hemorrhagic stroke, the most commonly filled antihypertensive prescription was ACE inhibitor in all groups (Table 4). Antihypertensive prescriptions were filled by 64.5%–77.5% of patients, and few patients filled prescriptions for the optimal combination of ACE inhibitor and diuretic. In the unadjusted analysis, Chinese patients were less likely than South Asian or other Canadian patients to fill any antihypertensive agent prescriptions ($p = 0.003$), including optimal ACE inhibitor and diuretic combination therapy ($p < 0.001$). After adjustment for baseline characteristics, Chinese patients remained less likely than other Canadian patients to fill prescriptions for the optimal combination of ACE inhibitor and diuretic (adjusted OR 0.51 [95% CI 0.38–0.69]) (Table 5). South Asian patients were more likely than other Canadian patients to fill prescriptions for any antihypertensive agent (adjusted OR 1.73 [95% CI 1.21–2.49]) and for the optimal combination of ACE inhibitor and diuretic (adjusted OR 1.31 [95% CI 0.91–1.88]).

### Table 5: Multivariable analysis of filling of prescriptions for secondary prevention therapy after acute stroke by ethnicity

| Stroke type; medication | Chinese v. other Canadians | South Asian v. other Canadians |
|-------------------------|---------------------------|-------------------------------|
| **Ischemic**            |                           |                               |
| ACE inhibitor or diuretic | 0.70 (0.64–0.76)          | 0.96 (0.86–1.06)              |
| ACE inhibitor + diuretic | 0.63 (0.56–0.70)          | 0.88 (0.78–0.99)              |
| ACE inhibitor or angiotensin-receptor blocker | 0.97 (0.89–1.06) | 1.05 (0.95–1.16) |
| Any antihypertensive    | 0.92 (0.83–1.02)          | 1.06 (0.93–1.20)              |
| Statin                  | 0.97 (0.88–1.07)          | 1.10 (0.98–1.24)              |
| Statin, ACE inhibitor or diuretic | 0.78 (0.71–0.86) | 0.96 (0.85–1.07) |
| Statin + ACE inhibitor or diuretic | 0.64 (0.55–0.74) | 1.01 (0.87–1.17) |
| Any antihypertensive or statin | 0.89 (0.80–0.99) | 0.99 (0.87–1.14) |
| Any antihypertensive + statin | 0.99 (0.91–1.09) | 1.16 (1.03–1.29) |
| Warfarin†               | 0.75 (0.59–0.95)          | 0.88 (0.60–1.28)              |
| **Primary intracerebral hemorrhagic** |                     |                               |
| ACE inhibitor or diuretic | 0.69 (0.57–0.83)          | 1.64 (1.20–2.24)              |
| ACE inhibitor + diuretic | 0.51 (0.38–0.69)          | 1.31 (0.91–1.88)              |
| ACE inhibitor or angiotensin-receptor blocker | 0.79 (0.65–0.96) | 1.75 (1.28–2.40) |
| Any antihypertensive agent | 0.82 (0.67–1.01)         | 1.73 (1.21–2.49)              |

Note: ACE = angiotensin-converting-enzyme.
*Adjusted for income quintile, age, sex, admitting physician (family physician v. specialist), prior medication use, and history of atrial fibrillation, hypertension, diabetes, dyslipidemia, myocardial infarction or congestive heart failure.
†Among patients with atrial fibrillation.
Interpretation

Although some prescriptions for secondary prevention therapy were filled by similar proportions of Chinese, South Asian and other Canadian patients, smaller proportions of Chinese patients filled prescriptions for the preferred combination of ACE inhibitor, diuretic and statin, and for anticoagulation therapy for atrial fibrillation following ischemic stroke. Similarly, after primary intracerebral hemorrhagic stroke, Chinese patients were less likely to fill prescriptions for preferred antihypertensive therapy with an ACE inhibitor and a diuretic. South Asian patients, in contrast, were just as likely as or more likely than other Canadian patients to fill prescriptions for secondary prevention treatment after acute ischemic stroke or intracerebral hemorrhagic stroke.

Our study provides new data on secondary prevention treatment among these ethnic groups and extends previous work that focused on other components of stroke care. Xian and colleagues identified similar or greater provision of in-hospital stroke care in Asian populations in the United States: Asian patients with intracerebral hemorrhage had higher odds of receiving deep vein thrombosis prophylaxis and dysphagia screening than white patients. In a previous study of 12 stroke centres in Ontario, we found similar receipt of rehabilitative services, admission to stroke units and brain imaging among ethnic groups. In contrast, a community-based stroke study in New Zealand showed that Asian patients were less likely than white patients to be using antihypertensive medications before stroke. Our finding of lower use of some secondary prevention treatments is consistent with studies in hypertension, diabetes and acute myocardial infarction that uniformly showed lower rates of filling of prescriptions for ACE inhibitors in Chinese populations compared to other Canadians. The reasons underlying ethnic differences in filling of prescriptions for secondary prevention treatment are likely multifactorial. There may be differences in health-seeking behaviours in Chinese populations. However, studies indicate that Chinese Canadians are just as likely to visit their family doctor as the general population. There may also be cultural differences in the patient’s willingness to fill prescriptions owing to cost, preference for alternative therapies, mistrust of Western medications and differing beliefs regarding modifiers of stroke risk. Reasons may also include provider–patient communication barriers and provider bias. There may be also greater concern by physicians and patients regarding adverse medication side effects in some ethnic groups. Asian patients have been reported to have increased ACE-inhibitor–induced cough compared to other groups. In the current study, there was no difference in prescription filling of either ACE inhibitor or angiotensin-receptor blocker (since the latter is a common alternative when patients do not tolerate ACE inhibitor) between Chinese and other Canadian patients in either the ischemic stroke subgroup or the intracerebral hemorrhagic subgroup. Our study also identified considerable underfilling of warfarin prescriptions after ischemic stroke among Chinese patients with atrial fibrillation despite the substantive reductions in recurrent stroke risk with this treatment. There may be reluctance to prescribe anticoagulants to Chinese patients with atrial fibrillation given the potentially higher risk of intracranial hemorrhage with these agents. More aggressive prescribing in South Asians may reflect health care providers’ heightened concern for their high vascular risk.

Strengths and limitations

A strength of this study is the use of a large, unselected population for analysis of prescription filling for secondary prevention treatment after stroke across 3 ethnic groups. There are also several limitations. First, we used surname algorithms instead of self-reported ethnicity, and the remaining group “other” was heterogeneous, with about 90% being white. However, surname algorithms are fairly specific, which allowed for conservative estimates of ethnic differences. We did not have information on lipid levels, blood pressure, renal function, severity of stroke or residual deficits. However, previous analysis of patients with acute stroke did not identify any significant difference in baseline blood pressure or stroke severity scores (Canadian Neurological Scale) after acute ischemic stroke or intracerebral hemorrhage in these ethnic groups. Finally, we were not able to identify medications purchased without a prescription (i.e., acetylsalicylic acid), medications purchased out of province or out of country, and prescriptions that were not filled by patients or, if filled, not consumed.

Conclusion

Although some prescriptions for secondary prevention treatment were filled to a similar extent across ethnic groups, Chinese patients were less likely than South Asian or other Canadian patients to fill prescriptions for the optimal therapy bundle of ACE inhibitor, diuretic and statin, or for warfarin. The clinical significance of these ethnic differences in provision of secondary prevention treatments is substantial. Combination treatment with an ACE inhibitor and a diuretic is associated with a reduction in recurrent stroke of 43% and a reduction in vascular events of 40%. Warfarin is associated with a reduction of risk of recurrent stroke of 47% among those with atrial fibrillation. Statin therapy is associated with a vascular risk reduction of 25% following stroke. Given the substantial benefits associated with these treatments, there is urgent need to improve secondary medication prescribing and/or primary adherence in stroke populations, especially Canadians of Chinese descent. Further study is needed to understand the causal factors for the lower filling of prescriptions for these secondary prevention treatments among Chinese patients and whether choice of antihypertensive affects recurrent risk of stroke in Asian populations.

References

1. Canada at a glance 2012. Ottawa: Statistics Canada. Available: www.statcan.gc.ca/pub/12-581-x/2012000/pop-eng.htm (accessed 2017 Feb. 1).
2. 2011 National Household Survey: data tables (modified 2017 Feb. 14). Available: http://www12.statcan.gc.ca/nhs-enm/2011/dp-pd/dt-tu/rp-eng.cfm?LANG=E&APVTH=t&DETAIL=0&DM=0&FL=0&FREE=0&CG=0&ID=0&GR=0&GRP=1&PID=105396&PRID=0&PTYPE=105277&S=0&SHOWALL=0&SUB=0&Temporal=2011&THEME=95&VID=0&VNAMEE=E&VNAMEF= (accessed 2017 Feb. 1).
3. Hoeffer EM, Rastogi S, Kim MO, et al. The Asian population 2010: 2010 census briefs. Suitland (MD): United States Census Bureau; 2012. Available: www.census.gov/prod/cen2010/briefs/c2010br-11.pdf (accessed 2017 Feb. 1).
4. Yang G, Wang Y, Zang Y, et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 2013;381:1587-2015.
5. Gueyffier F. Editorial comment — secondary prevention of stroke: beyond meta-analyses. Stroke 2003;34:2748-9.
6. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 11 506 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
7. Gray J, Millett C, Saxena S, et al. Ethnicity and quality of diabetes care in a health system with universal coverage: population-based cross-sectional survey in primary care. J Gen Intern Med 2007;22:1317-20.
8. Webster RA, Thompson DR, Davidson PM. The first 12 weeks following discharge from hospital: the experience of Gujarati South Asian survivors of acute myocardial infarction and their families. Contemp Nurse 2003;13:288-99.
9. King KM, LeBlanc P, Carr W, et al. Chinese immigrants’ management of their cardiovascular disease risk. West J Nurs Res 2007;29:804-26.
10. Rhodes P, Nocent A. A problem of communication? Diabetes care among Bangladeshi people in Bradford. Health Soc Care Community 2003;11:45-54.
11. Bhatia SK, Chong W, Prabhakaran D, et al. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke 2003;34:176-81.
12. Khan NA, Hemmelgarn B, Herman RJ, et al.; Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 — therapy. Can J Cardiol 2009;25:287-98.
13. Kernan WN, Ovbiagele B, Black HR, et al.; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischaemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-236.
14. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-62.
15. Quan H, Ghali WA, Dean S, et al. Development and validation of a surname list to define Chinese ethnicity. Med Care 2006;44:328-33.
16. Cummins C, Winter H, Cheng KK, et al. An assessment of the Nam Pechlan computer program for the identification of names of South Asian ethnic origin. J Public Health Med 1999;21:801-6.
17. Birman-Deych E, Waterman AD, Yan Y, et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005;43:480-5.
18. Xian Y, Holloway RG, Smith EE, et al. Racial/ethnic differences in process of care and outcomes among patients hospitalized with intracerebral hemorrhage. Stroke 2014;45:1241-50.
19. Khan NA, Quan H, Hill MD, et al. Risk factors, quality of care and prognosis in South Asian, East Asian and other Canadian patients with stroke. BMC Neurol 2013;13:74.
20. Peigné V, Carter K, Hackett M, et al. Ethnic disparities in incidence of stroke subtypes: Auckland Regional Community Stroke Study, 2002–2003. Lancet Neurol 2006;5:110-9.
21. Liu Q, Quan H, Chen G, et al. Antihypertensive medication adherence and mortality according to ethnicity: a cohort study. Can J Cardiol 2014;30:925-31.
22. Lai EF, Grubusiec M, Palepu A, et al. Cardiac medication prescribing and adherence after acute myocardial infarction in Chinese and South Asian Canadian patients. Contemp Nurse 2011;41:197-207.
23. Quan H, Fong A, De Coster C, et al. Variation in health services utilization among ethnic populations. CMAJ 2006;174:787-91.
24. Lawton J, Ahmad N, Hallowell N, et al. Perceptions and experiences of taking oral hypoglycaemic agents among people of Pakistani and Indian origin: qualitative study. BMJ 2005;330:1247.
25. McDowell SE, Coleman JJ, Ferrer RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006;332:1377-81.
26. Horii M, Connolly SJ, Zhu J, et al.; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013;44:1891-6.
27. Collins R, Armitage J, Parish S, et al.; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.

Affiliations: Division of General Internal Medicine (Khan, Palepu), University of British Columbia; Centre for Health Evaluation & Outcomes Sciences (Khan, Palepu), Vancouver, BC; Division of General Internal Medicine (McAlister) and Patient Health Outcomes Research and Clinical Effectiveness Unit (McAlister), University of Alberta, Edmonton, Alta; Divisions of Clinical Epidemiology (Pilate) and General Internal Medicine (Pilate), Department of Medicine, McGill University; The Research Institute of the McGill University Health Centre (Pilate), Montreal, Que.; Departments of Community Health Sciences (Quan, Hill) and Clinical Neurosciences (Hill), University of Calgary, Calgary, Alta.; Institute for General Clinical Research (Fang, Kapral); Division of General Internal Medicine (Kapral), Department of Medicine, University of Toronto, Toronto, Ont.

Contributors: Nadia Khan, Moira Kapral, Hude Quan and Anita Palepu conceived the study. Nadia Khan, Louise Pilote, Michael Hill, Anita Palepu, Finlay McAlister, Hude Quan, and Moira Kapral contributed to the study design. Nadia Khan and Moira Kapral contributed to data collection, and Nadia Khan, Moira Kapral and Jingming Fang contributed to data analysis. All of the authors contributed to interpretation of the data, writing the manuscript and revising the manuscript for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

Funding: This study was funded by the Heart and Stroke Foundation of Canada. Nadia Khan receives salary support from the Michael Smith Foundation for Health Research. Hude Quan and Finlay A. McAlister’s salaries are supported by Alberta Innovates – Health Solutions. Moira Kapral was supported by a Career Investigator Award from the Heart and Stroke Foundation of Canada.

Disclaimer: This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by the ICES or the Ontario MOHLTC is intended or should be inferred. All inferences, opinions, and conclusions drawn in this report are those of the authors and do not reflect the opinions or policies of Population Data BC.

Supplemental information: For reviewer comments and the original submission of this manuscript, please see www.cmajopen.ca/content/5/3/E702/suppl/DC1.